Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor—N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00118: Is Retroperitoneal Lymph Node Dissection Without Adjuvant Chemotherapy Enough for All Patients with Pathologic Stage II Nonseminoma Germ Cell Tumor?

Isamu Tachibana; Sean Q. Kern; Antoin Douglawi; Yan Tong; Mohammad Mahmoud; Timothy A. Masterson; Nabil Adra; Richard S. Foster; Lawrence H. Einhorn; Clint Cary

doi:10.1016/j.eururo.2022.09.018

Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor—N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00118: Is Retroperitoneal Lymph Node Dissection Without Adjuvant Chemotherapy Enough for All Patients with Pathologic Stage II Nonseminoma Germ Cell Tumor?

Isamu Tachibana^*, Sean Q. Kern, Antoin Douglawi, Yan Tong, Mohammad Mahmoud, Timothy A. Masterson, Nabil Adra, Richard S. Foster, Lawrence H. Einhorn, Clint Cary

^*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	e20-e21
Journal	European Urology
Volume	83
Issue number	1
DOIs	https://doi.org/10.1016/j.eururo.2022.09.018
State	Published - Jan 2023
Externally published	Yes

Access to Document

10.1016/j.eururo.2022.09.018

Fingerprint

Dive into the research topics of 'Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor—N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00118: Is Retroperitoneal Lymph Node Dissection Without Adjuvant Chemotherapy Enough for All Patients with Pathologic Stage II Nonseminoma Germ Cell Tumor?'. Together they form a unique fingerprint.

Cite this

Tachibana, I., Kern, S. Q., Douglawi, A., Tong, Y., Mahmoud, M., Masterson, T. A., Adra, N., Foster, R. S., Einhorn, L. H., & Cary, C. (2023). Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor—N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00118: Is Retroperitoneal Lymph Node Dissection Without Adjuvant Chemotherapy Enough for All Patients with Pathologic Stage II Nonseminoma Germ Cell Tumor? European Urology, 83(1), e20-e21. https://doi.org/10.1016/j.eururo.2022.09.018

Tachibana, Isamu ; Kern, Sean Q. ; Douglawi, Antoin et al. / Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re : Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor—N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00118: Is Retroperitoneal Lymph Node Dissection Without Adjuvant Chemotherapy Enough for All Patients with Pathologic Stage II Nonseminoma Germ Cell Tumor?. In: European Urology. 2023 ; Vol. 83, No. 1. pp. e20-e21.

@article{2158df883bec4e5e9c4ecb9a787403fa,

title = "Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor—N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00118: Is Retroperitoneal Lymph Node Dissection Without Adjuvant Chemotherapy Enough for All Patients with Pathologic Stage II Nonseminoma Germ Cell Tumor?",

author = "Isamu Tachibana and Kern, {Sean Q.} and Antoin Douglawi and Yan Tong and Mohammad Mahmoud and Masterson, {Timothy A.} and Nabil Adra and Foster, {Richard S.} and Einhorn, {Lawrence H.} and Clint Cary",

year = "2023",

month = jan,

doi = "10.1016/j.eururo.2022.09.018",

language = "English",

volume = "83",

pages = "e20--e21",

journal = "European Urology",

issn = "0302-2838",

number = "1",

}

Tachibana, I, Kern, SQ, Douglawi, A, Tong, Y, Mahmoud, M, Masterson, TA, Adra, N, Foster, RS, Einhorn, LH & Cary, C 2023, 'Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor—N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00118: Is Retroperitoneal Lymph Node Dissection Without Adjuvant Chemotherapy Enough for All Patients with Pathologic Stage II Nonseminoma Germ Cell Tumor?', European Urology, vol. 83, no. 1, pp. e20-e21. https://doi.org/10.1016/j.eururo.2022.09.018

Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor—N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00118: Is Retroperitoneal Lymph Node Dissection Without Adjuvant Chemotherapy Enough for All Patients with Pathologic Stage II Nonseminoma Germ Cell Tumor? / Tachibana, Isamu; Kern, Sean Q.; Douglawi, Antoin et al.
In: European Urology, Vol. 83, No. 1, 01.2023, p. e20-e21.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re

T2 - Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor—N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00118: Is Retroperitoneal Lymph Node Dissection Without Adjuvant Chemotherapy Enough for All Patients with Pathologic Stage II Nonseminoma Germ Cell Tumor?

AU - Tachibana, Isamu

AU - Kern, Sean Q.

AU - Douglawi, Antoin

AU - Tong, Yan

AU - Mahmoud, Mohammad

AU - Masterson, Timothy A.

AU - Adra, Nabil

AU - Foster, Richard S.

AU - Einhorn, Lawrence H.

AU - Cary, Clint

PY - 2023/1

Y1 - 2023/1

UR - http://www.scopus.com/inward/record.url?scp=85143778917&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2022.09.018

DO - 10.1016/j.eururo.2022.09.018

M3 - Letter

C2 - 36195478

AN - SCOPUS:85143778917

SN - 0302-2838

VL - 83

SP - e20-e21

JO - European Urology

JF - European Urology

IS - 1

ER -

Tachibana I, Kern SQ, Douglawi A, Tong Y, Mahmoud M, Masterson TA et al. Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor—N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00118: Is Retroperitoneal Lymph Node Dissection Without Adjuvant Chemotherapy Enough for All Patients with Pathologic Stage II Nonseminoma Germ Cell Tumor? European Urology. 2023 Jan;83(1):e20-e21. doi: 10.1016/j.eururo.2022.09.018